Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe COVID-19 Disease Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
No Longer Available No phase listed Expanded access

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

NCT04352985
View directory record Official record
Conditions
Septic Shock, Endotoxemia, COVID, Corona Virus Infection, Sepsis, Severe
Interventions
Toraymyxin PMX-20R (PMX Cartridge)
Device
Lead sponsor
Spectral Diagnostics (US) Inc.
Industry
Eligibility
18 Years and older
U.S. locations
3
States / cities
Farmington, Connecticut • Washington D.C., District of Columbia • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Jul 23, 2026, 2:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness

NCT05175690
View directory record Official record
Conditions
COVID19
Interventions
Diagnostic Software as Medical Device
Diagnostic Test
Lead sponsor
AudibleHealth AI, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab for Patients With Cancer and COVID-19 Disease

NCT04370834
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

NCT04426695
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

NCT04470544
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Camostat Mesilate, Standard of Care
Drug · Other
Lead sponsor
Alan Bryce
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated No phase listed Observational

Serology to COVID-19 for Recording Exposures and Evaluating Needs

NCT04566965
View directory record Official record
Conditions
Covid19, Coronavirus, SARS-CoV Infection
Interventions
SARS-CoV-2
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
232 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 23, 2026, 2:24 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Tele-health Enabled Clinical Trial for COVID-19

NCT04489628
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
Vitamin D3 or Placebo, Doctella telehealth monitoring
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Sargramostim Use in COVID-19 to Recover Patient Health

NCT04707664
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Sargramostim, Placebo
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jul 23, 2026, 2:24 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Jul 23, 2026, 2:24 PM EDT
Completed No phase listed Observational Results available

The Impact of Vaccination on Severity of Illness in COVID-19

NCT04912700
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 vaccine
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
11,834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jul 23, 2026, 2:24 PM EDT
Completed No phase listed Observational

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

NCT07090486
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

NCT05381454
View directory record Official record
Conditions
Respiratory Viral Infection, Antiviral Treatment, COVID-19
Interventions
Mitoquinone/mitoquinol mesylate
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional

Nebulised Heparin in Patients With Severe COVID-19

NCT04545541
View directory record Official record
Conditions
Covid19, Respiratory Failure
Interventions
Nebulised unfractionated heparin (UFH)
Drug
Lead sponsor
Australian National University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

NCT05081388
View directory record Official record
Conditions
SARS-CoV-2
Interventions
REGN14256, imdevimab, casirivimab + imdevimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

NCT04467840
View directory record Official record
Conditions
COVID-19, Lung Infection
Interventions
Opaganib, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

NCT04494386
View directory record Official record
Conditions
Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions
Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
Biological · Other
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

NCT05541861
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 2 Interventional Results available

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View directory record Official record
Conditions
COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 23, 2026, 2:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Related Health and Infection Control Practices Among Dentists

NCT04423770
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
No intervention
Other
Lead sponsor
American Dental Association
Other
Eligibility
18 Years and older
Enrollment
2,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Jul 23, 2026, 2:24 PM EDT
Terminated Phase 1 Interventional Results available

Camostat With Bicalutamide for COVID-19

NCT04652765
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, Coronavirus Infection
Interventions
Camostat Mesilate, Bicalutamide 150 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 23, 2026, 2:24 PM EDT